The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 327.00
Bid: 328.50
Ask: 330.50
Change: -7.50 (-2.24%)
Spread: 2.00 (0.609%)
Open: 329.00
High: 332.50
Low: 321.00
Prev. Close: 334.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Wed, 15th Dec 2021 09:33

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

----------

FTSE 100

----------

SOCGEN CUTS BAE SYSTEMS PRICE TARGET TO 620 (660) PENCE - 'BUY'

----------

RBC CUTS ANGLO AMERICAN PRICE TARGET TO 3,150 (3,300) PENCE - 'OUTPERFORM'

----------

JEFFERIES CUTS ANTOFAGASTA PRICE TARGET TO 1,700 (1,800) PENCE - 'BUY'

----------

RBC CUTS BP PRICE TARGET TO 410 (425) PENCE - 'SECTOR PERFORM'

----------

RBC RAISES SHELL B PRICE TARGET TO 2,500 (2,350) PENCE - 'OUTPERFORM'

----------

GOLDMAN SACHS CUTS UNILEVER PRICE TARGET TO 4,700 (4,800) PENCE - 'BUY'

----------

GOLDMAN RAISES TESCO PRICE TARGET TO 335 (320) PENCE - 'BUY'

----------

GOLDMAN RAISES J SAINSBURY PRICE TARGET TO 270 (265) PENCE - 'NEUTRAL'

----------

BARCLAYS CUTS VODAFONE PRICE TARGET TO 165 (170) PENCE - 'OVERWEIGHT'

----------

DEUTSCHE BANK RAISES PEARSON PRICE TARGET TO 625 (570) PENCE - 'HOLD'

----------

BARCLAYS CUTS DCC TO 'UNDERWEIGHT' ('EQUAL WEIGHT') - TARGET 5,550 (6,900) PENCE

----------

CREDIT SUISSE CUTS RENTOKIL INITIAL TARGET TO 600 (630) PENCE - 'OUTPERFORM'

----------

CITIGROUP CUTS RENTOKIL TO 'NEUTRAL' (BUY) - PRICE TARGET 650 (600) PENCE

----------

FTSE 250

----------

BERENBERG CUTS HARBOUR ENERGY TO 'HOLD' (BUY) - PRICE TARGET 350 (425) PENCE

----------

RBC CUTS HARBOUR ENERGY TO 'SECTOR PERFORM' (OUTPERFORM) - PRICE TARGET 480 (650) PENCE

----------

RBC RAISES OXFORD BIOMEDICA PRICE TARGET TO 1,450 (14,30) PENCE - 'OUTPERFORM'

----------

BARCLAYS CUTS DOMINO'S PIZZA TO 'UNDERWEIGHT' (EQUAL WEIGHT) - PRICE TARGET 495 (500) PENCE

----------

UBS RAISES BALFOUR BEATTY PRICE TARGET TO 390 (370) PENCE - 'BUY'

----------

CREDIT SUISSE RAISES BEAZLEY PRICE TARGET TO 415 (350) PENCE - 'NEUTRAL'

----------

OTHER MAIN MARKET AND AIM

----------

BOFA INITIATES POD POINT WITH 'BUY' - TARGET 450 PENCE

----------

RBC RAISES TULLOW OIL TO 'SECTOR PERFORM' (UNDERPERFORM) - PRICE TARGET 90 (70) PENCE

----------

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
28 Jan 2022 16:19

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

Read more
28 Jan 2022 12:13

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

Read more
28 Jan 2022 10:27

Oxford BioMedica to acquire 80% ownership of new US virus business

Oxford BioMedica to acquire 80% ownership of new US virus business

Read more
28 Jan 2022 09:56

Oxford Biomedica creates venture with Homology, launches £80m fundraise

(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.

Read more
17 Jan 2022 09:32

Oxford Biomedica starts search for new CEO as Dawson steps down

Oxford Biomedica starts search for new CEO as Dawson steps down

Read more
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.